Commercialization Has Recurring Topology: How Acelen’s $3 Billion SAF Bet Reveals the Hidden Grammar of Deployment
For years, biorefinery commercialization has often been discussed as if it were a linear process: develop the technology, raise the capital, build the plant, scale the market. But after reviewing tens of thousands of deployment stories across fuels, chemicals, carbon, SAF, hydrogen, biomaterials and infrastructure systems, a different picture begins to emerge. Commercialization behaves less […]











